Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-30490 is a synthetic opioid analgesic structurally related to carfentanil and fentanyl. It was first synthesized by Janssen Pharmaceutica during structure–activity relationship studies of fentanyl analogues. R-30490 is notable for being the most selective agonist for the mu-opioid receptor among tested fentanyl derivatives, exhibiting extremely high potency—only slightly less than carfentanil. Despite its pharmacological activity, it has never been introduced for medical use in humans; its primary application has been as an animal tranquilizer and in research settings. Like other potent opioids in this class, side effects include itching, nausea, and potentially life-threatening respiratory depression[1][2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on R-30490.